Full Year Statutory Accounts
Released
Released
Announcement PDF
29 August 2025
Manager, Company Announcements
ASX Limited
Level 4
20 Bridge Street
SYDNEY NSW 2000
Via E-Lodgement
Dear Sir/Madam
Mayne Pharma Group Limited
Final Report and accompanying announcement
Please find attached the following documents relating to the results for the year ended 30 June
2025.
•
•
Appendix 4E
Annual Financial Statements
This announcement comprises the information required by ASX Listing Rule 4.3A.
Yours faithfully,
Mayne Pharma Group Limited
Laura Loftus
Company Secretary
RESULTS FOR ANNOUNCEMENT TO THE MARKET
APPENDIX 4E – PRELIMINARY FINAL REPORT
%
30 JUNE
30 JUNE
2025
2024
$’000
$’000
408,095
388,399
Profit / (loss) from continuing operations before income tax expense
(83,296)
(190,087)
Profit / (loss) from continuing operations after income tax expense
(90,071)
(168,619)
Profit / (loss) from discontinued operations after income tax expense
(3,765)
(5,614)
Profit / (loss) after income tax
(93,836)
(174,233)
(93,836)
(174,233)
-
-
(93,836)
(174,233)
5,800
902
(88,036)
(173,331)
(88,036)
(173,331)
-
-
(88,036)
(173,331)
(2.22)
(1.45)
2025
2024
$
$
Basic earnings per share
(1.19)
(2.19)
Diluted earnings per share
(1.19)
(2.19)
Nil
Nil
CHANGE
Revenue from ordinary activities
5%
Attributable to:
Equity holders of the parent
Non-controlling interests
Other comprehensive profit/(loss) after income tax expense
Total comprehensive profit/(loss) for the period
Attributable to:
Equity holders of the parent
Non-controlling interests
Net tangible assets per ordinary share (1)
Final dividend in respect of the financial year ended 30 June per share
Refer to the Review of Operations and Likely Developments and the accompanying ASX announcement dated 29 August 2025 for a brief
commentary on the results.
1.
Includes right-of-use lease assets.
Financial Report 2025
MAYNE PHARMA GROUP LIMITED
ABN 76 115 832 963
FOR THE YEAR ENDED 30 JUNE 2025
(PRIOR CORRESPONDING PERIOD: YEAR ENDED 30 JUNE 2024)
CONTENTS
DIRECTORS’ REPORT
2
REMUNERATION REPORT (AUDITED)
14
AUDITOR’S INDEPENDENCE DECLARATION
22
CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME
24
CONSOLIDATED STATEMENT OF FINANCIAL POSITION
25
CONSOLIDATED STATEMENT OF CASH FLOWS
26
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
27
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
28
CONSOLIDATED ENTITY DISCLOSURE STATEMENT
65
DIRECTORS’ DECLARATION
66
INDEPENDENT AUDITOR’S REPORT
67
GLOSSARY
72
DIRECTORS’ REPORT
The Directors of Mayne Pharma Group Limited (‘the Company’) present their report together with the financial report of the Company and its
controlled entities (collectively the ‘Group’ or ‘Consolidated Entity’ or ‘Mayne Pharma’) for the year ended 30 June 2025 and the Auditor’s Report
thereon. The information set out below is to be read in conjunction with the Remuneration Report set out on pages 14 to 25, which forms part of this
Directors’ Report.
DIRECTORS
The Directors of the Company during the financial year and up to the date of this report are set out below. Directors were in office for this entire
period unless otherwise noted.
Mr Frank Condella, Chair
Mr Shawn Patrick O’Brien, Managing Director and CEO
Mr Patrick Blake
Ms Ann Custin
Mrs Anne Lockwood
Dr Kathryn MacFarlane
Mr David Petrie
Prof Bruce Robinson, AC
The Directors’ qualifications, other listed company directorships, experience and special responsibilities are detailed on pages 10 and 11 of this report.
The qualifications and experience of the Company Secretary are detailed on page 11 of this report.
DIRECTORS’ MEETINGS
The number of Directors’ meetings (including meetings of committees of Directors) and number of meetings attended by each of the Directors of the
Company during the 2025 financial year are:
BOARD
NOMINATION
COMMITTEE
REMUNERATION & PEOPLE
COMMITTEE
SCIENCE, TECHNOLOGY &
MEDICAL COMMITTEE
ATTENDED2
HELD1
ATTENDED2
HELD1
ATTENDED2
HELD1
ATTENDED2
HELD1
ATTENDED2
HELD1
3
33
32
-
4
1
1
10
9
-
-
Mr S O’Brien3,4
33
33
-
6
-
-
-
10
-
-
Mr P Blake
33
33
6
6
-
-
10
10
-
-
Ms A Custin4
33
32
6
6
-
-
-
1
-
-
Mrs A Lockwood
33
33
6
6
-
-
-
-
-
-
Dr K MacFarlane
33
31
-
-
1
1
-
-
2
2
Mr D Petrie
33
33
6
6
-
-
10
10
-
-
Prof B Robinson
33
32
-
-
1
1
-
-
2
2
Mr F Condella
1.
2.
3.
4.
AUDIT & RISK COMMITTEE
This column shows the number of meetings held during the period the Director was a member of the Board or Committee.
This column shows the number of meetings attended.
Mr O’Brien and Mr Condella are not members of the Audit and Risk Committee however they attend meetings at the Chair’s invitation.
Mr O’Brien and Ms Custin are not members of the Remuneration and People Committee however they attend meetings at the Chair’s invitation.
SIGNIFICANT CHANGES IN THE STATE OF AFFAIRS
Scheme Implementation Deed (SID)
Mayne Pharma entered into a scheme implementation deed with Cosette Pharmaceuticals, Inc (Cosette) dated 20 February 2025 under which Cosette
proposed to acquire all of the shares in Mayne Pharma (via a subsidiary Cosette Australia BidCo Pty Ltd) by way of scheme of arrangement between
Mayne Pharma and its shareholders (Scheme) for consideration of $7.40 per share.
On 15 May 2025 the Court approved the distribution of the Scheme booklet to Mayne Pharma shareholders.
On 17 May 2025 Mayne Pharma received correspondence from Cosette asserting that a Mayne Material Adverse Change had occurred and that
certain obligations under the SID had been triggered, in particular the obligation on the parties to promptly consult with each other in good faith for
10 business days, as a precondition to a party seeking to exercise rights to terminate the SID for a Material Adverse Change. Mayne Pharma rejected
Cosette’s contention that there had been any Material Adverse Change.
On 4 June 2025 Mayne Pharma received a notice purporting to terminate the SID from Cosette and has since received other notices from Cosette
purporting to terminate the SID on different grounds, to the extent its previously asserted grounds of termination are found to be invalid, as
announced to the ASX by Mayne Pharma. Mayne Pharma re-affirms its view there is no lawful basis for Cosette to terminate the SID.
On 18 June 2025 Mayne Pharma convened the Mayne Pharma shareholder scheme meeting to consider and vote on the scheme. Shareholders voted
overwhelmingly in favour of the scheme.
As a result of the matters outlined above, the Court postponed the second court hearing (which approves implementation of the scheme) until 18
September 2025 and the scheme has yet to be implemented. As at the date of this report, Mayne Pharma remains an ASX listed company. The matters
outlined above will be considered by the Court (unless otherwise resolved) between 22 September and mid-October 2025. It is anticipated that the
second Court hearing, necessary for the implementation of the scheme, will be rescheduled to a date in mid-late October, after the dispute between
Mayne Pharma and Cosette has been determined by the Court. The FIRB approval necessary for the scheme to proceed remains outstanding as at
the date of this report and needs to be obtained prior to the scheme being implemented. Any material changes to the anticipated timetable or
material matters related to the scheme will be announced by Mayne Pharma through the ASX announcements platform.
Mayne Pharma Group Limited Financial Statements for the year ended 30 June 2025
2
Product acquisitions
On 22 April 2025 Mayne Pharma announced the acquisition and licence of the US rights to TWYNEO® and EPSOLAY®. TWYNEO® (tretinoin and benzoyl
peroxide) Cream, 0.1%/3% is manufactured pursuant to NDA 214902 and is indicated for the topical treatment of acne vulgaris in adults and paediatric
patients 9 years of age and older. EPSOLAY® is manufactured pursuant to NDA 214510 and is indicated for the treatment of inflammatory lesions of
rosacea in adults 18 years of age and older.
PRINCIPAL ACTIVITIES
Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising branded women’s health and dermatology
pharmaceuticals.
Mayne Pharma has a 40-year track record of innovation and success in developing new oral drug delivery systems and these technologies have been
successfully commercialised in numerous products that continue to be marketed around the world.
Mayne Pharma has a product development and manufacturing facility based in Salisbury, Australia with expertise in the formulation of complex oral
and topical dose forms including modified-release products and poorly soluble compounds.
REVIEW OF OPERATIONS AND LIKELY DEVELOPMENTS
Summary of financial performance
Set out below is a summary of the financial performance attributable to Mayne Pharma shareholders for the 2025 financial year (FY25) compared to
the prior corresponding period (pcp).
This summary includes non-IFRS Accounting financial information that is stated excluding certain non-operating income and expense items. The
results are set out this way as the Directors consider them to be a meaningful comparison from period to period that are useful for the users of this
financial report as they provide additional and relevant information that reflect the underlying performance of the business. Key measures of earnings
considered by management in operating the business and assessing performance are earnings before interest, tax, depreciation, amortisation and
impairment (‘EBITDA’) and Adjusted EBITDA.
2025
$M
2024
$M
CHANGE ON PCP
$M
Reported Revenue continuing operations
408.1
388.4
19.7
Reported Gross profit continuing operations
247.3
218.8
28.5
Reported Gross profit %
60.6%
56.3%
SALES AND PROFIT
Adjusted EBITDA
47.0
22.9
Adjustments1
(28.6)
(115.4)
24.1
86.8
Reported EBITDA continuing operations
18.4
(92.5)
110.9
Depreciation / Amortisation
(69.3)
(68.5)
(0.8)
Reported Profit / (Loss) Before Interest and Tax from continuing operations
(50.9)
(161.0)
110.1
Net interest (expense) / income
(0.1)
2.4
(2.5)
Foreign exchanges gains/(losses) financing activities
2.5
(1.1)
3.6
Earn-out & deferred consideration liabilities discount unwind
(34.8)
(30.3)
(4.5)
Reported Profit / (Loss) Before Tax continuing operations
(83.3)
(190.1)
106.8
Income tax credit / (expense)
(6.8)
21.5
(28.3)
Reported Net Profit / (Loss) After Tax attributable to Mayne Pharma shareholders
continuing operations
(90.1)
(168.6)
78.5
1.
Current year adjustments are included in the table below.
The reconciliation of reported results (from continuing operations) and adjusted results for the current year is as follows:
SALES AND PROFIT
REPORTED
ATTRIBUTABLE TO
MEMBERS JUNE
2025
$M
EARN-OUT
REASSESSMENTS1
$M
RESTRUCTURING2
$M
DILIGENCE &
TRANSACTION
EXPENSES
$M
DERIVATIVE FAIR
VALUE
ADJUSTMENT4
$M
LITIGATION5
$M
ADJUSTED JUNE
2025
$M
Revenue
408.1
408.1
Gross profit
247.3
247.3
Gross profit %
60.6%
60.6
EBITDA
18.4
Depreciation /
Amortisation
(69.3)
16.6
1.6
8.5
(1.7)
3.5
47.0
(69.3)
Asset impairments
PBIT
(50.9)
Net finance costs
(32.4)
PBT
(83.3)
1.
2.
3.
4.
5.
16.6
1.6
8.5
(1.7)
3.5
16.6
1.6
8.5
(1.7)
3.5
(22.3)
(32.4)
(54.7)
Non-cash debit arising from the net increase in earn-out and deferred consideration liabilities with the majority relating to ANNOVERA®.
Restructuring costs related to organisational transformation to simplify the operating model.
Diligence and transaction costs including litigation costs related to the SID entered with Cosette.
Fair value adjustment relating to the convertible notes derivative.
Drug pricing and health care investigations, US Department of Justice and related litigation costs.
Mayne Pharma Group Limited Financial Statements for the year ended 30 June 2025
3
Review of operations
The Group recorded revenue for continuing operations of $408.1m, up 5.1% on the pcp and gross profit for continuing operations was $247.3m, up
13.0% on pcp.
Gross profit margin for continuing operations as a percentage of revenue was 60.6% (2024: 56.3%) which reflects the growth of the Women’s Health
business (higher relative profitability business).
The reported loss before tax from continuing operations was $83.3m and the net loss after tax was $90.1m.
The impact of exchange rate movements on the Company’s balance sheet is recognised in the Foreign Currency Translation Reserve (FCTR) which
increased by $5.8m during the year.
Expenses
Research, development medical and regulatory affairs expense (total costs less amounts qualifying for capitalisation) were $17.9m, a decrease in the
expense of $2.3m (11%) on the pcp.
JUNE
2025
$M
JUNE
2024
$M
Total R&D, medical and regulatory affairs costs incurred
18.1
20.2
Development costs capitalised
(0.2)
-
R&D, medical and regulatory affairs expensed
17.9
20.2
Marketing and distribution expenses increased by $6.3m (5%) to $136.8m. The majority of marketing and distribution costs relate to the US businesses
and hence are subject to currency rate translation – the currency translation impact was to increase the FY25 expense by $1.6m (compared to FY24
translation rate). In USD terms marketing and distribution costs increased by US$2.4m due to increased activity for Adelaide Apothecary and
continued development of Women’s Health assets with costs such as speaker programs and samples.
Finance costs of $37.3m (2024: $36.1m) include the unwinding of discounts associated with earn-out liabilities and deferred liabilities which increased
to $34.8m from $30.3m in the pcp. The earnouts discount unwind includes NEXTSTELLIS® $11.8m (2024: $12.1m) and TXMD $22.0m (2024: $16.3m).
Included in finance costs are foreign exchange losses relating to financing activities of $2.5m gain (2024: $1.1m loss)
There were no impairments in the current period (2024: $nil).
Administration and other expenses decreased by $19.3m to $128.6m. This category includes non-cash and other non-operating items such as:
•
•
•
•
•
•
•
•
•
Amortisation of intangible assets which was $61.0m (2024: $59.7m);
Class Action Settlement (net of insurance recovery) nil (2024: $33.3m);
Share based payments expense of $4.0m (2024: $4.1m);
Drug pricing investigations and related litigation costs of $3.5m (2024: $1.3m);
Diligence and transactions costs including litigation costs related to the SID entered with Cosette of $8.5m (2024: nil);
A specific doubtful debt nil (2024: $7.8m);
Foreign exchange losses of $0.3m (2024: nil);
Fair value movement on a derivative of $1.7m gain (2024: $2.8m gain); and
Restructuring expenses of $1.7m (2024: $0.9m).
Excluding these items, administration and other expenses were $51.3m compared to $51.4m in 2024.
Tax
Tax expense of $6.8m for continuing operations and tax benefit of $1.1m for discontinued operations comprised:
•
•
•
Current period income tax expense for the year to 30 June 2025 of $0.5m;
A decrease in current year tax benefit in respect of prior years of $0.5m; and
Deferred income tax expense of $4.7m.
Mayne Pharma Group Limited Financial Statements for the year ended 30 June 2025
4
Financial position
Set out below is a summary of the financial position as at 30 June 2025 compared to the position as at 30 June 2024.
BALANCE SHEET EXTRACT
2025
$M
2024
$M
CHANGE ON PCP
$M
CHANGE ON PCP
%
Cash
59.8
110.1
(50.3)
(46)
Marketable securities
40.6
39.2
1.4
4
Receivables
180.6
193.2
(12.6)
(7)
Inventory
50.6
74.6
(24.0)
(32)
Income tax receivable
1.3
14.5
(13.2)
(91)
PP&E
53.1
46.7
6.4
14
Intangible assets
545.8
568.6
(22.8)
(4)
Other assets
82.8
96.3
(13.5)
(14)
Total assets
1,014.6
1,143.2
(128.6)
(11)
Interest-bearing debt (including lease liabilities)
41.3
38.8
2.5
6
Trade and other payables
174.3
244.5
(70.2)
(29)
Other financial liabilities
409.1
381.8
27.3
7
Other liabilities
19.6
23.9
(4.3)
(18)
Total liabilities
644.3
689.0
(44.7)
(6)
Equity
370.3
454.2
(83.9)
(18)
The material changes to the operating assets and liabilities of the business were as follows:
Cash
Cash decreased by $50.3m to $59.8m compared to 30 June 2024. In addition to cash, the Company also holds marketable securities of $40.6m which
increased compared to 30 June 2024 by $1.4m.
Inventory, receivables and trade payables
Receivables reduced during FY25 providing a cash release of $12.6m (excludes the insurance receivable included in FY24 balance of $4.7m). Inventory
also decreased significantly providing a cash release of $25.8m as a result of general inventory efficiency improvements. These decreases occurred
while revenue increased. Trade and other payables reduced as a result of lower inventory levels and in FY24 there was a delay in invoicing by certain
vendors which are now current.
Intangible assets
Intangible assets decreased by $22.8m compared to the balance at 30 June 2024. The movement comprised of:
•
•
•
•
An increase of $26.0m for the TWYNEO® and EPSOLAY® acquisition;
An increase of $0.2m for capitalised development costs;
A decrease of $61.0m for amortisation; and
An increase of $12.0m due to foreign currency translation as the AUD / USD exchange rate decreased from 0.6647 at 30 June 2024 to 0.6529 at
30 June 2025.
Property, plant & equipment
Property, plant and equipment increased by $6.4m compared to the balance at 30 June 2024. The movement comprised of:
•
•
An increase of $11.1m for additions (net of the government grant funds received during the year of $1.2m); and
A decrease of $4.7m for depreciation.
Interest bearing liabilities
Interest bearing liabilities (excluding lease liabilities) increased to $35.2m from $31.6m at 30 June 2024. Convertible notes were issued in December
2022 to support the acquisition of the TXMD licensed assets. The convertible notes are repayable as a fixed AUD amount at maturity (if not converted).
The change in the liability represents the amortisation of borrowing costs. The borrowing costs are amortised over the term of the loan so that, at
maturity, the book value of the loan will be equal to the amount repayable ($41.6m) (if not converted prior to maturity).
Other financial liabilities
The major items included in other financial liabilities as at 30 June 2025 were the earn-out liabilities and deferred consideration for the NEXTSTELLIS®
distribution rights and the TXMD earn-out and deferred consideration liabilities.
Other financial liabilities increased by $27.2m from 30 June 2024 due to:
•
•
•
•
•
•
An increase of $34.8m due to the unwinding of the discount for the various earn-out liabilities and deferred consideration liabilities including
$11.8m relating to the NEXTSTELLIS® deferred consideration liability and $22.0m relating to the TXMD earn-out liabilities;
An increase of $16.6m due to re-assessments which included the TXMD liabilities which were reassessed upwards by $19.3m due to increased
revenue forecasts for the products. Several other earn-outs were reassessed downwards;
A decrease of $39.8m due to payments made which included $20.0m (US$13m) paid to Population Council;
An increase of $9.5m due to the acquisition of TWYNEO® and EPSOLAY®;
A decrease of $1.7m due to the change in the fair value of the convertible notes related derivative; and
An increase relating to foreign currency translation of $7.8m.
Mayne Pharma Group Limited Financial Statements for the year ended 30 June 2025
5
Equity
Shareholder equity movements include the current year loss (including discontinued operations) of $93.8m and other comprehensive income of
$5.8m for a net movement of $88.0m. Other equity movements included share-based payments reserve net increase $2.3m.
Cash flow
A summary of the net operating cash flows is as follows:
2025
$M
2024
$M
Net operating cash flows before working capital movements
44.9
(0.7)
Working capital (investments) / releases
5.8
(14.6)
Net Operating cash flows before Class Action settlement
50.7
(15.3)
Class Action settlement (net of insurance)
(33.2)
-
Net Operating cash flows
17.5
(15.3)
Less estimated cashflows relating to discontinued operations outflows / (inflows)
7.9
23.4
Estimated net operating cashflows from continuing operations
25.4
8.1
Operating cash flow was impacted by the Class Action net cash settlement (in July 2024) and discontinued operations including payments for certain
operating expenses and payments for gross-to-net liabilities for the divested Retail Generics business. Operating cashflows includes an IRS tax refund
(CARES Act) of $13.2m. Continuing operations working capital efficiency gains enabled a net working capital release even though there was an increase
in revenue.
Operating cashflows related to discontinued operations were determined in a manner consistent with total operating cashflows in that the profit/loss
from discontinued operations was adjusted for non-cash items and working capital movements relating to the discontinued operations.
Earnout payments are deferred / variable consideration for asset acquisitions (or asset disposals in the case of the Metrics sale) and are disclosed in
investing cashflows and therefore are not included in operating cashflows. Refer investing cashflows below.
Investing cash flows
2025
$M
2024
$M
(68.1)
53.4
Notable cash flows during the period included:
•
•
•
•
•
$12.3m payments for capital expenditure;
$1.2m government grant received (related to capital expenditure);
$16.5m payments for intangible asset acquisitions relating to the TWYNEO® and EPSOLAY® acquisition (part of the consideration is deferred and
will be settled post year-end – also refer movements in earn-out and deferred consideration liabilities);
$0.5m additional investment in marketable securities; and
Earn-out and deferred settlement payments totalling $39.8m. This includes $20m (US$13m) paid to Population Council in relation to ANNOVERA®.
Financing cash flows
2025
$M
2024
$M
(0.6)
(19.9)
Notable cash flows during the period included:
•
•
Net interest receipts $3.4m; and
Lease payments (right-of-use) assets $3.8m.
Cash on hand plus marketable securities total $100.4m at 30 June 2025 representing a decrease of $48.9m from 30 June 2024 for the reasons outlined
above.
Reporting Segments
The Consolidated Entity operates in three operating segments being International, Women’s Health and Dermatology. During FY23, the Consolidated
Entity sold the MCS segment and the Retail Generics business and has therefore included MCS and Retail Generics in discontinued operations (refer
Note 6). The segment note in the financial statements (Note 2) shows the revenue, gross profit (GP), direct operating expenses (opex) and the direct
contribution (being the GP less direct opex) for each segment.
Dermatology
2025
$M
2024
$M
CHANGE %
Revenue
154.1
174.9
(11.9)
Gross profit
82.8
83.9
(1.3)
Gross profit %
54%
48%
Direct opex (including lease depreciation)
(42.6)
(39.6)
Direct contribution
40.2
44.3
(9.2)
Nature of operations
The Dermatology division distributes established dermatology products in the US.
Mayne Pharma Group Limited Financial Statements for the year ended 30 June 2025
6
FY25 performance
The segment’s sales were $154.1m down 12% on FY24. Gross profit was $82.8m, down 1% on FY24 and direct contribution decreased to $40.2m
compared to the pcp of $44.3m. The performance of the division declined compared to the previous year due to competitive launches against
ORACEA®, loss of some insurance coverage on RHOFADE®, and continued declines in the branded oral antibiotic markets, primarily affecting DORYX®.
Women’s Health
2025
$M
2024
$M
CHANGE %
Revenue
178.4
142.8
24.9
Gross profit
142.9
113.5
26.0
Gross profit %
80%
79%
Direct opex (including lease depreciation)
(80.9)
(78.2)
Direct contribution
62.0
35.2
76.0
Nature of operations
The Women’s Health Division distributes Women’s Health branded products in the US. This Division’s products include NEXTSTELLIS®, ANNOVERA®,
IMVEXXY® and BIJUVA®.
FY25 performance
The segment’s sales were $178.4m, up 25% on FY24, gross profit was $142.9m, up 26% on FY24 and direct contribution was $62.0m, an improvement
of 76% on the pcp. FY25 results reflect a continued increase in operating leverage in Women’s Health, all products experienced unit growth. FY25
results were negatively impacted by higher product returns than expected, related to expiry date of inventory acquired from TXMD and by a lag effect
from the sales force refresh which began in FY24 and completed in the first half of FY25.
International
2025
$M
2024
$M
CHANGE %
Revenue
75.6
70.7
7.0
Gross profit
21.5
21.3
0.9
Gross profit %
29%
30%
Direct opex
(14.1)
(12.4)
7.4
9.0
Direct contribution
(17.4)
Nature of operations
International’s revenues and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical
products globally (ex-US) and the provision of contract development and manufacturing services to third party customers.
FY25 performance
The International reporting segment’s revenues were $75.6m, up 7% on FY24, gross profit was $21.5m, up 1% on FY24 and direct contribution
decreased 17% to $7.4m. The segment’s revenue growth was primarily driven by sustained demand for KADIAN® in the Canadian market, alongside
continuing strong domestic sales of oxycodone and UROREC®. Gross profit was impacted by temporary production disruptions during the first half
which reduced production output. Production output recovered in the second half returning to expected levels. Additional opex included investment
for future growth (sales team expansion and IT system upgrade costs).
The Salisbury modernisation project is concluding, with the installation of new equipment including a high-speed blister packing line and bottling line
(the encapsulator started commercial production June 2024). Mayne Pharma has successfully met all conditions of the Federal Government’s Modern
Manufacturing Initiative (MMI) Grant and received the full $4.8 million funding as of June 2025.
Strategy
The Company’s core strategic priorities include the following:
KEY PRIORITIES
ACTIVITIES
• Drive growth to further increase operating leverage, through sharpened focus on sales execution
and some targeted marketing efforts
• Maximise long term value of assets, via IP portfolio management and product education via Key
Opinion Leaders (KOLs)
•
Deliver profit potential of current
Women’s Health asset portfolio
•
Differentiate channel solution to
enable preferred solution for
patients, prescribers and partners
•
•
Ensure channel strategy processes are easy to use, enabling status as preferred solution
Capital efficient and accretive business development to further the Dermatology portfolio, driving
growth in revenues and margins
•
•
Drive international profit via new
revenue streams and continuation of •
modernisation
•
Leverage capacity created by operational improvements to grow and further operating leverage
Complete modernisation upgrade program to improve productivity and capabilities, with targeted
maintenance capex thereafter
Expansion of KAPANOL®/KADIAN® in ex-AU markets
Mayne Pharma Group Limited Financial Statements for the year ended 30 June 2025
7
Material business risks
The Board accepts that taking and managing risk is central to building shareholder value and that the Board is responsible for the Group’s risk
management strategy. Management is responsible for implementing the Board’s strategy and for developing a control infrastructure designed to
identify and mitigate risks across operations.
The Company has implemented a Risk Management Policy with a detailed, structured approach to systematically identify, rank, mitigate, and monitor
risks. This effort, led by the Compliance and Risk function, is additive to ongoing risk management responsibilities that all employees engage in as
they accomplish their daily tasks according to Company requirements. The Company maintains a risk register and material risks are regularly reported
on and discussed with management, the Audit and Risk Committee and the Board. Further details of the Company’s approach to risk identification
and management are outlined in its Corporate Governance Statement.
The following table details some of the material risks that could affect Mayne Pharma’s business and operations but are not the only risks Mayne
Pharma faces. Other risks besides those detailed below could adversely affect Mayne Pharma’s business and operations.
RISK
Business and strategy
NATURE OF THE RISK
•
Changes in market dynamics for oral
contraceptives
•
Delayed implementation of growth strategy for
the dermatology distribution channel
•
Inability to meet educational and scientific
engagement needs of the healthcare community
for our full portfolio
•
Inherent competition risk to portfolio
•
Future acquisitions, licences, and investments
could negatively affect operating results, dilute
equity ownership, increase debt, or cause
significant expense
•
Inability to drive accretive growth effectively
•
Healthcare policy changes and legislative reform
in the US healthcare system
•
Potential for US tariffs to be introduced on
products currently imported
ACTIONS/PLANS TO MITIGATE
•
Select and staff experienced personnel and
business partners
•
Implement disciplined and risk balanced
product selection process
•
Establish strong systems and processes to
monitor and manage the performance of each
product and customer relationship
•
Conduct detailed due diligence of acquisitions
and engage third parties for expert advice
where appropriate
•
Prepare detailed operational/integration plans
for acquisitions following completion
•
Develop business models and systems to move
closer to patients
•
Diversify channels to market
•
Mitigations to tariff risk for products may
include su
Share your feedback
Discover